Group Therapy for Nicotine Dependence
This 3-group randomized clinical trial will develop and evaluate a Mindfulness-Based
Addiction Treatment (MBAT) for nicotine dependence. Mindfulness reflects a purposeful
control of attention and can be learned through training in attentional control procedures.
Current cigarette smokers (N=550; 400 in formal study; up to 80-150 pilot) will be randomly
assigned to Usual Care (UC), Standard Treatment (ST) or MBAT. UC will be four 5-10 minute
counseling sessions following the problem-solving approach in the Treating Tobacco Use and
Dependence Clinical Practice Guideline (Guideline). ST is a standard smoking cessation group
program using a problem-solving/coping skills approach. MBAT is a group smoking cessation
program derived from Mindfulness-Based Stress Reduction (MBSR) and Mindfulness-Based
Cognitive Therapy. MBAT will not alter the basic mindfulness approach used in MBCT and MBSR,
but will replace depression-related material with smoking cessation strategies from the
Guideline. All participants will receive nicotine patches and self-help materials. MBAT
mechanisms and effects will be assessed using "implicit" cognitive psychological measures
and computer-administered questionnaires. Participants will be tracked from baseline through
4 (UC) or 8 (ST and MBAT) treatment visits and follow-up visits 1 and 23 weeks
The overarching goals are to evaluate MBAT's efficacy for nicotine dependence and the
mechanisms and effects posited to mediate MBAT's impact on abstinence.
Primary specific aims are to:
1. Examine the effects of MBAT on abstinence rates
2. Examine the effects of MBAT on mindfulness/metacognitive awareness, attentional
control, smoking automaticity, smoking associations in memory, negative affect,
depression, stress, affect regulation expectancies, self-efficacy, withdrawal, and
coping across the pre- and post-cessation period, and whether these variables mediate
MBAT effects on abstinence.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Participant involvement up to 32 weeks. Smoking status questionnaire with biochemical verification. Point-prevalence abstinence at Week 23 is defined as a self-report of no smoking during the previous 7 days and a saliva cotinine level of <20 ng/ml.
David W Wetter, Ph.D.
UT MD Anderson Cancer Center
United States: Federal Government
|University of Texas MD Anderson Cancer Center||Houston, Texas 77030|